Esperion Therapeutics, Inc. (ESPR) — 10-Q Filings

10-Q Filings (6)

• Esperion's Net Loss Widens to $84.5M Despite Strong Product Sales Growth — Nov 6, 2025 Risk: high
  Esperion Therapeutics, Inc. reported a significant increase in total revenues for the nine months ended September 30, 2025, reaching $234.689 million, a decreas
• Esperion's Q2 Product Sales Soar, But Collaboration Revenue Plummets — Aug 13, 2025 Risk: high
  Esperion Therapeutics, Inc. reported a significant increase in product sales, reaching $40.274 million for the three months ended June 30, 2025, up from $28.302
• Esperion Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Esperion Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first
• Esperion Therapeutics Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Esperion Therapeutics, Inc. filed its Q3 2024 10-Q report on November 7, 2024, covering the period ending September 30, 2024. The company, based in Ann Arbor, M
• Esperion Therapeutics Q2 Revenue Rises — Aug 12, 2024 Risk: medium
  Esperion Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported product revenue of $102.8 million for the second quarter of
• Esperion Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk:
  Esperion Therapeutics, Inc. (ESPR) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Esperion Therapeutics reported financial results for the quarter

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX